FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	e 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person — Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]								Nelationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455				3. Date of Earliest Transaction (Month/Day/Year) 06/14/2010									re title below)		(specify below)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
ROCKVI	LLE, MD	20850									-	Form filed by	More than One	Reporting Person			
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Der	rivat	ive Securities	Acquir	ed, Disposed	l of, or Bend	eficially Own	ed		
(Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Da) any (Month/Day/		Date, if		. 8)	4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D)		of (D)	Owned Following Reported Transaction(s)			wnership of orm:	Beneficial Ownership		
Common	Stock						code v		iount (D)	+	3,000)			
Reminder:	Report on a	separate line for eac	Table II - 1	Derivativ	ve Se	ecurities	s Acq	Perso conta form	ons aine disp	who respon	m are n ently va	ot required alid OMB co	to respon	d unless the		74 (9-02)	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number		6. Date Exercisa Expiration Date (Month/Day/Ye		isable and ite	7. Title Amour Underl Securit	nt of ying ties 3 and 4)	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Beneficial	
				Code	V	(A)	(D)	Date Exercisat	ble	Expiration Date	Title	Amount or Number of Shares					
Stock Options (right- to-buy)	\$ 1.17	06/14/2010		A		20,000)	<u>(1)</u>		06/14/2020	Comn	20.000	\$ 0	20,000	D		
Stock Options (right- to-buy)	\$ 1.28							06/01/20	010	06/01/2019	Comn	120.000		20,000	D		
Stock Options (right- to-buy)	\$ 3.24							06/30/20	009	06/30/2018	Comn	non k 20,000		20,000	D		
Stock Options (right- to-buy)	\$ 1.40							06/11/20	008	06/11/2017	Comn			20,000	D		
Stock Options (right- to-buy)	\$ 1.20							05/01/20	007	05/01/2016	Comn	20,000		20,000	D		

Reporting Owners

Donordino Como or Norma / Addinos	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X						

Explanation of Responses:

- * If the form is filed by more than one reporting person, \emph{see} Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 14, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.